Low-dose rituximab is effective in pemphigus

British Journal of Dermatology

Volumn 166, Issue 2, 2012, Pages 405-412

  Horvath B ^a   Huizinga, J ^a   Pas, H H ^a   Mulder, A B ^a   Jonkman, M F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CLEMASTINE; DAPSONE; DESMOGLEIN 1; DESMOGLEIN 1 ANTIBODY; DESMOGLEIN 3; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISOLONE; PREDNISONE; RITUXIMAB;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HERPES ZOSTER; HUMAN; HUMAN CELL; LOW DRUG DOSE; LYMPHOCYTE COUNT; MALE; NAUSEA; NEUTROPENIA; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; RELAPSE; REMISSION; SEPSIS; SINGLE DRUG DOSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; DERMATOLOGIC AGENTS; DESMOGLEIN 1; DESMOGLEIN 3; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; OFF-LABEL USE; PEMPHIGUS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 84856215488     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10663.x     Document Type: Article

References (41)

1. Martin LK, Werth V, Villanueva E, et al. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009; 1: CD006263.
2. Hertl M, Eming R, Borradori L,. Rituximab (anti-CD20 monoclonal antibody)-ultimate or first choice in pemphigus? Dermatology 2007; 214: 275-7.
3. Carr DR, Heffernan MP,. Off-label uses of rituximab in dermatology. Dermatol Ther 2007; 20: 277-87.
4. McLaughlin P, White CA, Grillo-Lopez AJ, Maloney DG,. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology 1998; 12: 1763-9.
5. Furst DE, Keystone EC, Fleischmann R, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010; 69 (Suppl. 1): i2-29.
6. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007; 56: 3896-908.
7. Arin MJ, Hunzelmann N,. Anti-B-cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus-an update. Eur J Dermatol 2005; 15: 224-30.
8. Borradori L, Lombardi T, Samson J, et al. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 2001; 137: 269-72.
9. Heizmann M, Itin P, Wernli M, et al. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 2001; 66: 142-4.
10. Schadlow MB, Anhalt GJ, Sinha AA,. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus. J Drugs Dermatol 2003; 2: 564-7.
11. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR,. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 1772-9.
12. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357: 545-52.
13. Cianchini G, Corona R, Frezzolini A, et al. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol 2007; 143: 1033-8.
14. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-66.
15. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-95.
16. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G,. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007; 2: 932-7.
17. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-9.
18. Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58: 1043-6.
19. Kim JH, Kim YH, Kim MR, Kim SC,. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol 2011; 165: 646-51.
20. van Duinen KF, Mulder AB, Jonkman MF,. Rituximab voor de behandeling van refractaire auto-immuun-blaarziekten. Ned Tijdsch Derm Ven 2009; 19: 116-22.
21. Salopek TG, Logsetty S, Tredget EE,. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 2002; 47: 785-8.
22. Faurschou A, Gniadecki R,. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol 2008; 47: 292-4.
23. Morrison LH,. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol 2004; 51: 817-19.
24. Fuertes I, Guilabert A, Mascaro JM Jr, Iranzo P,. Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature. Dermatology 2010; 221: 13-16.
25. Alter M, Wittmann M, Volker B, et al. Successful treatment of pemphigus foliaceus with rituximab. Report of 3 cases. Hautarzt 2009; 60: 743-8.
26. Goebeler M, Herzog S, Brocker EB, Zillikens D,. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol 2003; 149: 899-901.
27. Shimanovich I, Nitschke M, Rose C, et al. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 2008; 158: 382-8.
28. Eming R, Nagel A, Wolff-Franke S, et al. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol 2008; 128: 2850-8.
29. Goh MS, McCormack C, Dinh HV, et al. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br J Dermatol 2007; 156: 990-6.
30. Kasperkiewicz M, Shimanovich I, Ludwig RJ, et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2011; 65: 552-8.
31. Schmidt E, Seitz CS, Benoit S, et al. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007; 156: 352-6.
32. Niedermeier A, Worl P, Barth S, et al. Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur J Dermatol 2006; 16: 266-70.
33. Hertl M, Zillikens D, Borradori L, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008; 6: 366-73.
34. Chaiwatanatorn K, Lee N, Grigg A, et al. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 2003; 121: 913-18.
35. Rios-Fernandez R, Gutierrez-Salmeron MT, Callejas-Rubio JL, et al. Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases. Br J Dermatol 2007; 157: 1271-3.
36. Dupuy A, Viguier M, Bedane C, et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 2004; 140: 91-6.
37. Abasq C, Mouquet H, Gilbert D, et al. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol 2009; 145: 529-35.
38. Mouquet H, Musette P, Gougeon ML, et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 2008; 128: 2859-69.
39. Arin MJ, Engert A, Krieg T, Hunzelmann N,. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 2005; 153: 620-5.
40. Muller R, Hunzelmann N, Baur V, et al. Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris. Dermatol Res Pract 2010; 2010: 321950.
41. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC,. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613-20.